
The recommendations are learnt to have been approved by the DCGI. In August 2020, US-based vaccine maker Novavax Inc. had announced a licence agreement with the SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate, in low and middle-income countries and India.
from Top India News- News18.com
Read The Rest:news18..